APA

Lui A., Mulder K., Brezden-Masley C., Vickers M., Monzon J., Kennecke H., Goel R., Vos L., Ghosh S., Marginean H., Fields A., Maroun J. & Spratlin J. (20190327). A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. : Investigational new drugs.

Chicago

Lui Arthur, Mulder Karen, Brezden-Masley Christine, Vickers Michael, Monzon Jose, Kennecke Hagen, Goel Rakesh, Vos Larissa, Ghosh Sunita, Marginean Horia, Fields Anthony, Maroun Jean and Spratlin Jennifer. 20190327. A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. : Investigational new drugs.

Harvard

Lui A., Mulder K., Brezden-Masley C., Vickers M., Monzon J., Kennecke H., Goel R., Vos L., Ghosh S., Marginean H., Fields A., Maroun J. and Spratlin J. (20190327). A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. : Investigational new drugs.

MLA

Lui Arthur, Mulder Karen, Brezden-Masley Christine, Vickers Michael, Monzon Jose, Kennecke Hagen, Goel Rakesh, Vos Larissa, Ghosh Sunita, Marginean Horia, Fields Anthony, Maroun Jean and Spratlin Jennifer. A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. : Investigational new drugs. 20190327.